| Not Yet Recruiting | CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) NCT04933422 | Crimson Biopharm Inc. | Phase 1 |
| Not Yet Recruiting | PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients NCT06448286 | Jonsson Comprehensive Cancer Center | Phase 3 |
| Not Yet Recruiting | A Study for Cerebral Open Flow Microperfusion NCT07089758 | Mayo Clinic | N/A |
| Not Yet Recruiting | Imaging Acetadote Metabolism in Glioblastoma NCT07387666 | University of Texas Southwestern Medical Center | EARLY_Phase 1 |
| Not Yet Recruiting | Phase I Trial of pH Resections of GBM at VA NCT07218367 | VA Office of Research and Development | Phase 1 |
| Not Yet Recruiting | Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wi NCT07385846 | Jennifer Leddon | Phase 1 |
| Not Yet Recruiting | Oral Gallium Maltolate for Recurrent Glioblastoma NCT07515924 | Medical College of Wisconsin | EARLY_Phase 1 |
| Not Yet Recruiting | A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy NCT07422896 | Catalina Lee Chang | Phase 1 |
| Not Yet Recruiting | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During NCT07493447 | Eben Rosenthal | EARLY_Phase 1 |
| Not Yet Recruiting | Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma NCT07392957 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Not Yet Recruiting | APT-weighted and Diffusion MRI for Characterizing Tumor Infiltration in High-Grade Gliomas NCT07532031 | IRCCS Ospedale San Raffaele | — |
| Not Yet Recruiting | Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) NCT07389278 | Sabine Mueller, MD, PhD | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma NCT07464925 | Tetragon Biosciences Ltd | Phase 1 |
| Recruiting | Senicapoc and Perampanel for Newly Diagnosed Glioblastoma NCT07284069 | Aarhus University Hospital | EARLY_Phase 1 |
| Recruiting | Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study NCT05653635 | Centre Paul Strauss | Phase 2 |
| Not Yet Recruiting | Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma NCT07356973 | CRISM Therapeutics LTD | Phase 2 |
| Not Yet Recruiting | Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. NCT07439172 | The Cooper Health System | Phase 2 |
| Not Yet Recruiting | Pharmacoscopy for Patients With Refractory Primary Brain Tumors NCT06804655 | University of Zurich | Phase 2 |
| Recruiting | A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During NCT07042620 | SonoClear AS | N/A |
| Recruiting | Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors NCT07411690 | Medical University of Warsaw | — |
| Recruiting | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma NCT07480941 | Beijing Biotech | Phase 1 |
| Recruiting | Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Vers NCT07413796 | Medical University of Warsaw | N/A |
| Active Not Recruiting | Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas NCT07448480 | Blokhin's Russian Cancer Research Center | — |
| Recruiting | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System fo NCT07225621 | Alpheus Medical, Inc. | Phase 2 |
| Not Yet Recruiting | Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastom NCT07365280 | ZSky Biotech Inc | Phase 2 |
| Not Yet Recruiting | Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma NCT06749925 | University of Sao Paulo General Hospital | Phase 3 |
| Not Yet Recruiting | MRinRT: Swansea University and SWWCC Collaboration Study. NCT07365124 | Swansea Bay University Health Board | — |
| Not Yet Recruiting | Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients NCT07274397 | Beta Emitting Accurate Monitored Systems | N/A |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Recruiting | OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients NCT07426848 | Royal College of Surgeons, Ireland | N/A |
| Not Yet Recruiting | Vortioxetine for Newly Diagnosed Glioblastoma NCT07284628 | University of Zurich | Phase 2 |
| Recruiting | Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care NCT07195591 | GT Medical Technologies, Inc. | Phase 3 |
| Recruiting | Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Gliobla NCT06991101 | Baptist Health South Florida | Phase 2 |
| Not Yet Recruiting | Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas NCT06455189 | Case Comprehensive Cancer Center | Phase 1 |
| Not Yet Recruiting | Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Gli NCT07211841 | Centre Hospitalier Universitaire, Amiens | N/A |
| Not Yet Recruiting | Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow NCT06492486 | Tata Memorial Centre | Phase 2 |
| Recruiting | Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH NCT06964815 | Istituto Oncologico Veneto IRCCS | N/A |
| Recruiting | Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblast NCT06831526 | Washington University School of Medicine | EARLY_Phase 1 |
| Recruiting | Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Gliob NCT07263438 | Centre Hospitalier Universitaire Vaudois | Phase 2 |
| Recruiting | Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent G NCT07100730 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 |
| Recruiting | Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma NCT07476794 | Sunnybrook Health Sciences Centre | Phase 2 |
| Recruiting | Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients NCT07461948 | Jonsson Comprehensive Cancer Center | Phase 3 |
| Recruiting | Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma NCT07145112 | University of California, Davis | Phase 1 |
| Not Yet Recruiting | Clinical and Treatment Determinant of Prognosis in Glioblastoma NCT07197086 | Assiut University | — |
| Recruiting | Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4) NCT07488754 | Medical University of Warsaw | N/A |
| Completed | Use of Fluorescence in Gliomas NCT07499141 | Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria | — |
| Recruiting | A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma NCT07093814 | Guangzhou Virotech Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Multicenter, Prospective Study for Glioblastoma Patients NCT07162324 | Larissa University Hospital | — |
| Recruiting | Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachyther NCT07141732 | Joint Stock Company European Medical Centre | Phase 1 |
| Not Yet Recruiting | A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and P NCT07173829 | University Hospital, Bordeaux | — |
| Recruiting | A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas NCT07003542 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | PH Sensitive MRI Based Resections of Glioblastoma NCT06176066 | University of California, Los Angeles | Phase 1 |
| Recruiting | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion NCT06333899 | Nationwide Children's Hospital | EARLY_Phase 1 |
| Recruiting | Molecular Imaging of Cancer-associated Fibroblasts in Glioblastoma: a FAPI PET/MR Study. NCT07119294 | Jules Bordet Institute | N/A |
| Recruiting | CUE-102 in Recurrent Glioblastoma NCT06917885 | David Reardon, MD | Phase 1 |
| Recruiting | CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy NCT06973096 | University of Pennsylvania | Phase 1 |
| Not Yet Recruiting | A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After t NCT07047066 | Tongji Hospital | Phase 2 |
| Recruiting | A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Rec NCT07134842 | University College, London | Phase 1 |
| Not Yet Recruiting | The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab NCT07052877 | Royal North Shore Hospital | — |
| Not Yet Recruiting | Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Pati NCT07029100 | Centre Henri Becquerel | N/A |
| Active Not Recruiting | A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent M NCT06614855 | James Markert, MD | Phase 1 |
| Not Yet Recruiting | Research on the Safety and Efficacy of Intraoperative Radiation Therapy in Malignant Cerebral Tumor NCT06929819 | First Affiliated Hospital, Sun Yat-Sen University | N/A |
| Recruiting | Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume NCT06719440 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | N/A |
| Withdrawn | Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy NCT05900908 | GT Medical Technologies, Inc. | Phase 4 |
| Recruiting | Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma NCT06613841 | Abramson Cancer Center at Penn Medicine | EARLY_Phase 1 |
| Recruiting | Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma NCT06934889 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Not Yet Recruiting | Patient's Derived Organoids for Drug Screening in Glioblastoma NCT06781372 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Not Yet Recruiting | CSF Proteomic Characterization of Glioblastomas NCT06845020 | Univeridad Autonoma de Guadalajara | — |
| Recruiting | A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma NCT06552260 | Ugonma Chukwueke | EARLY_Phase 1 |
| Recruiting | Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients with Brain Lesions. NCT06797661 | Erasme University Hospital | N/A |
| Recruiting | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed NCT06556563 | NovoCure GmbH | Phase 3 |
| Recruiting | Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma NCT05439278 | Severance Hospital | Phase 3 |
| Recruiting | A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma NCT06672575 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI NCT07121842 | Erasmus Medical Center | N/A |
| Not Yet Recruiting | Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery NCT06780592 | Huashan Hospital | Phase 2 |
| Not Yet Recruiting | Artificial Intelligence-Guided Radiotherapy Planning for Glioblastoma NCT06657027 | Hospital del Rio Hortega | — |
| Not Yet Recruiting | Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells in Glioblastoma NCT06764537 | Central Hospital, Nancy, France | N/A |
| Not Yet Recruiting | Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and NCT06477939 | Institut de cancérologie Strasbourg Europe | Phase 3 |
| Recruiting | Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression NCT06936046 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue NCT05756985 | Baptist Health South Florida | — |
| Recruiting | Key Longitudinal Associations With Risk and Glioblastoma Outcomes NCT06625684 | Duke University | — |
| Recruiting | PET-imaging of Two Vartumabs in Patients With Solid Tumors NCT06645808 | Var2 Pharmaceuticals | EARLY_Phase 1 |
| Withdrawn | Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma NCT05773664 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without NCT06496971 | NaviFUS Corporation | Phase 3 |
| Not Yet Recruiting | Optimizing Cytokine-Induced Killer Cells in Glioblastoma Patients NCT06684899 | IRCCS San Raffaele | — |
| Recruiting | Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblast NCT06329570 | NaviFUS Corporation | Phase 1 / Phase 2 |
| Recruiting | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas NCT06640582 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Development and Implementation of an Intervention Enhancing Involvement of Relatives to Patients With Acquired NCT06796335 | Rigshospitalet, Denmark | — |
| Recruiting | Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression NCT06975332 | Medical University of Warsaw | N/A |
| Recruiting | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects Wit NCT06102525 | Rznomics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma NCT07364786 | Peter Siesjö | Phase 2 |
| Completed | Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy NCT06625047 | Mayo Clinic | Phase 4 |
| Recruiting | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for NCT06607692 | Fundación de investigación HM | Phase 1 / Phase 2 |
| Recruiting | Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2) NCT06551909 | IRCCS San Raffaele | N/A |
| Recruiting | Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed NCT06222138 | Institut Claudius Regaud | N/A |
| Recruiting | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant NCT05843253 | Nationwide Children's Hospital | Phase 2 |
| Recruiting | Hypofractionated Radiotherapy NCT06740955 | The First Hospital of Jilin University | N/A |
| Recruiting | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma NCT06061809 | ImmunityBio, Inc. | Phase 2 |
| Recruiting | Targeted Pediatric High-Grade Glioma Therapy NCT05839379 | Nationwide Children's Hospital | — |
| Not Yet Recruiting | Targeted Survivin DC Cell Injection for the Treatment of GBM NCT06524063 | Beijing Tricision Biotherapeutics Inc | Phase 1 |
| Not Yet Recruiting | FET-PET-Guided Management of Pseudoprogression in Glioblastoma NCT06480721 | Veerle Ruijters | N/A |
| Not Yet Recruiting | Preoperative Preradiotherapy TTFields NCT06136611 | The Christie NHS Foundation Trust | N/A |
| Recruiting | Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening NCT06512311 | Medical University of Vienna | N/A |
| Completed | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial NCT06439420 | Virginia Commonwealth University | Phase 2 |
| Not Yet Recruiting | B-amyloid as a Marker for GBM Bioimaging NCT05820191 | Universidad Central del Caribe | Phase 2 |
| Withdrawn | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma NCT04629209 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Gl NCT06388733 | Ivy Brain Tumor Center | Phase 3 |
| Recruiting | A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence NCT06336291 | Philogen S.p.A. | Phase 2 |
| Recruiting | Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients NCT05990556 | First Affiliated Hospital, Sun Yat-Sen University | N/A |
| Recruiting | Psychological and Psychiatric prOfile in Glioblastoma and Head and Neck Cancer NCT06385132 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells NCT06186401 | Hideho Okada, MD, PhD | Phase 1 |
| Suspended | Glioblastoma Remote Monitoring and Care - Research Protocol NCT06129760 | Case Comprehensive Cancer Center | N/A |
| Recruiting | Escalated Dose Proton Therapy Within the Multimodality Treatment of Glioblastoma Patients NCT05768087 | University of Aarhus | N/A |
| Recruiting | Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma NCT05871021 | University Hospital Tuebingen | Phase 2 |
| Recruiting | Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progre NCT05565118 | Case Comprehensive Cancer Center | Phase 1 |
| Not Yet Recruiting | Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma NCT06368934 | Huashan Hospital | N/A |
| Recruiting | Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques NCT06623565 | Amsterdam UMC, location VUmc | N/A |
| Recruiting | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma NCT06418113 | Hospital San Carlos, Madrid | Phase 1 |
| Suspended | Investigational Imaging Technique During Brain Surgery NCT05513859 | Emory University | N/A |
| Active Not Recruiting | Immuno-Positron Emission Tomography (PET)-Glioma Study, a Proof-of-principle Imaging Study NCT05753995 | Kepler University Hospital | N/A |
| Unknown | Pinpointing the Factors Affecting Clinical Trial Experiences of Glioblastoma Patients NCT05728125 | Power Life Sciences Inc. | — |
| Terminated | A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients NCT05753007 | Mclean Hospital | Phase 2 |
| Suspended | Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma NCT04657146 | Duke University | — |
| Recruiting | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications NCT06161519 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Predictive Value of Soluble CD146 in Glioblastoma Patients NCT06001281 | Assistance Publique Hopitaux De Marseille | N/A |
| Recruiting | Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma NCT06108206 | Columbia University | N/A |
| Active Not Recruiting | Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent NCT05902169 | CarThera | Phase 3 |
| Recruiting | Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema NCT06710249 | Peter Siesjö | Phase 2 |
| Completed | Expectations and Needs of a Glioblastoma Caregiver NCT06490497 | Hopital Nord Franche-Comte | — |
| Recruiting | ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma NCT05917145 | Mayo Clinic | Phase 1 |
| Recruiting | Antisecretory Factor Glioblastoma Phase 2 NCT05669820 | Peter Siesjö | Phase 2 / Phase 3 |
| Recruiting | TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER NCT06924099 | NovoCure Ltd. | — |
| Recruiting | MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adapta NCT06041555 | Hospices Civils de Lyon | — |
| Recruiting | Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma NCT06183983 | Erasmus Medical Center | N/A |
| Recruiting | Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Mainten NCT06140875 | Charite University, Berlin, Germany | N/A |
| Withdrawn | The Addition of Chloroquine to Chemoradiation for Glioblastoma, NCT02432417 | Maastricht Radiation Oncology | Phase 2 |
| Completed | Glioblastoma Psychosocial Support Program NCT06038604 | Duke University | N/A |
| Not Yet Recruiting | Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma NCT06132438 | Charlotte Lemech | Phase 1 |
| Recruiting | Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospect NCT06113705 | Istituto Clinico Humanitas | N/A |
| Recruiting | A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) P NCT06072586 | St. Joseph's Hospital and Medical Center, Phoenix | EARLY_Phase 1 |
| Terminated | Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO) NCT06038760 | Ourotech, Inc. | — |
| Not Yet Recruiting | Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields NCT06017063 | University Hospital Tuebingen | N/A |
| Recruiting | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer NCT06058988 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | Azeliragon in MGMT Unmethylated Glioblastoma NCT05986851 | Cantex Pharmaceuticals | Phase 2 |
| Active Not Recruiting | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells NCT05664243 | In8bio Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma NCT05635734 | Cantex Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients Wi NCT05698199 | Immunomic Therapeutics, Inc. | Phase 1 |
| Completed | TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastom NCT03529448 | Grupo Español de Investigación en Neurooncología | Phase 1 / Phase 2 |
| Withdrawn | Monocyte Antigen Carrier Cells for Newly Diagnosed GBM NCT04741984 | Michael Gunn | Phase 1 |
| Active Not Recruiting | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Gliobla NCT05798507 | Emory University | EARLY_Phase 1 |
| Active Not Recruiting | IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma NCT05353530 | University of Florida | Phase 1 |
| Recruiting | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma NCT05879367 | Orbus Therapeutics, Inc. | Phase 1 |
| Recruiting | Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma NCT05954858 | Northwell Health | N/A |
| Recruiting | Pilot Trial for Treatment of Recurrent Glioblastoma NCT05432518 | AHS Cancer Control Alberta | EARLY_Phase 1 |
| Recruiting | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma NCT05698524 | University of Nebraska | Phase 1 |
| Withdrawn | Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma NCT05927610 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma NCT05938387 | CureVac | Phase 1 |
| Recruiting | Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG NCT05773326 | Nader Sanai | EARLY_Phase 1 |
| Unknown | Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-amino NCT05929456 | University Medical Center Groningen | Phase 1 |
| Recruiting | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors NCT05835687 | St. Jude Children's Research Hospital | Phase 1 |
| Suspended | GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM NCT05695976 | Duke University | — |
| Unknown | Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glio NCT05811793 | Second Affiliated Hospital of Nanchang University | N/A |
| Recruiting | Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) NCT05979064 | Northwell Health | N/A |
| Recruiting | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma NCT05557292 | Nicholas Butowski | Phase 1 |
| Withdrawn | Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma NCT05410301 | Varun Monga, MD | N/A |
| Unknown | Glioblastoma Imaging Using a Strong Iron-like Bloodpool Contrast Medium? NCT05656300 | Radboud University Medical Center | — |
| Recruiting | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) NCT05450744 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 |
| Active Not Recruiting | Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study NCT05781321 | Mayo Clinic | Phase 2 |
| Recruiting | CARv3-TEAM-E T Cells in Glioblastoma NCT05660369 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Active Not Recruiting | A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma NCT04485949 | Imvax | Phase 2 |
| Not Yet Recruiting | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma NCT05095441 | ImmVira Pharma Co. Ltd | Phase 1 |
| Recruiting | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas NCT05768919 | SignPath Pharma, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Gl NCT04900792 | Bryan Allen | Phase 1 |
| Active Not Recruiting | CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM NCT05168423 | University of Pennsylvania | Phase 1 |
| Recruiting | ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids NCT05629702 | University of Birmingham | Phase 2 |
| Recruiting | Methimazole in Patients With Progressive Glioblastoma NCT05607407 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | Venous Thromboembolism Prevention in Outpatients With Glioma NCT05683808 | University of Vermont Medical Center | Phase 2 |
| Recruiting | The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) NCT06146738 | Jasper Gerritsen | — |
| Suspended | Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients NCT04219475 | OncoHost Ltd. | — |
| Recruiting | Glutamate Inhibitors in Glioblastoma NCT05664464 | University of Zurich | Phase 1 / Phase 2 |
| Recruiting | The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) NCT06283927 | Jasper Gerritsen | — |
| Not Yet Recruiting | Biopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study. NCT05641220 | Erasmus Medical Center | — |
| Recruiting | The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) NCT06146725 | Jasper Gerritsen | — |
| Recruiting | The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma NCT06273176 | Erasmus Medical Center | — |
| Completed | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors NCT05538572 | Prelude Therapeutics | Phase 1 |
| Recruiting | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tu NCT05283330 | Orano Med LLC | Phase 1 |
| Unknown | Correlation Between Psychological Stress and Disease Progression in Newly Diagnosed Glioblastoma Patients NCT05515133 | Henan Provincial People's Hospital | — |
| Not Yet Recruiting | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Gli NCT05502991 | Henan Provincial People's Hospital | Phase 2 |
| Recruiting | Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). NCT06297512 | Iacopo Sardi | Phase 2 |
| Not Yet Recruiting | Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers NCT05541042 | Henan Provincial People's Hospital | — |
| Unknown | Personalized Trial in ctDNA-level-relapse Glioblastoma NCT05539339 | Henan Provincial People's Hospital | N/A |
| Completed | A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highe NCT05376800 | Boehringer Ingelheim | Phase 1 |
| Recruiting | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. NCT05686798 | Henry Ford Health System | Phase 1 |
| Active Not Recruiting | Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma NCT04319276 | Medical College of Wisconsin | Phase 1 |
| Recruiting | Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor NCT05590689 | Universität Münster | Phase 1 / Phase 2 |
| Unknown | Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma NCT05700955 | University of Louisville | Phase 1 |
| Completed | Supramarginal Resection in Glioblastoma Guided by Artificial Intelligence NCT05735171 | Hospital del Rio Hortega | N/A |
| Recruiting | Surgical Pembro +/- Olaparib w TMZ for rGBM NCT05463848 | L. Nicolas Gonzalez Castro, MD, PhD | Phase 2 |
| Active Not Recruiting | Tofacitinib in Recurrent GBM Patients NCT05326464 | University of Texas Southwestern Medical Center | Phase 3 |
| Active Not Recruiting | Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma NCT04922723 | West Virginia University | Phase 1 / Phase 2 |
| Completed | Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling NCT06600399 | Lanzhou University Second Hospital | — |
| Unknown | Safety and Efficacy of a New Approach to Delineating Clinical Target Volume of Glioblastoma NCT05512195 | Zhongnan Hospital | N/A |
| Terminated | A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma NCT05074992 | University College, London | Phase 2 |
| Active Not Recruiting | A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) NCT04752813 | BPGbio | Phase 2 |
| Active Not Recruiting | GammaTile and Stupp in Newly Diagnosed GBM NCT05342883 | GT Medical Technologies, Inc. | Phase 4 |
| Completed | Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors NCT05383872 | InSightec | N/A |
| Active Not Recruiting | Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma NCT05236036 | Northwestern University | Phase 1 |
| Completed | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects NCT06469138 | BerGenBio ASA | Phase 1 |
| Withdrawn | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants NCT03649464 | Oblato, Inc. | Phase 1 / Phase 2 |
| Completed | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors NCT05131815 | Cedars-Sinai Medical Center | N/A |
| Recruiting | Glioblastoma Targeted Treatment Option Maximization by WGS NCT05186064 | UMC Utrecht | N/A |
| Active Not Recruiting | Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma NCT05970757 | Erasmus Medical Center | N/A |
| Unknown | Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma NCT06279767 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 / Phase 2 |
| Recruiting | Evaluation of the CONVIVO System NCT05139277 | Dartmouth-Hitchcock Medical Center | N/A |
| Unknown | Glioblastoma Evaluation for Heterogeneity In RadioseNsitivity NCT05556382 | Istituto Clinico Humanitas | — |
| Withdrawn | Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Pr NCT05304663 | Philogen S.p.A. | Phase 1 |
| Withdrawn | A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma NCT04200066 | University of Rochester | Phase 1 |
| Active Not Recruiting | AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients NCT05182905 | Nader Sanai | EARLY_Phase 1 |
| Recruiting | Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma NCT04863950 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Completed | Brain Tumor Intraoperative Ultrasound Database NCT05062772 | Hospital del Rio Hortega | — |
| Terminated | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma NCT05267106 | Incyte Corporation | Phase 2 |
| Terminated | Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial NCT04825275 | Milton S. Hershey Medical Center | EARLY_Phase 1 |
| Completed | Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesions NCT05296122 | Clinical Laserthermia Systems AB | N/A |
| Terminated | Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas NCT04869449 | Milton S. Hershey Medical Center | EARLY_Phase 1 |
| Active Not Recruiting | A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Ca NCT05109728 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation NCT05271240 | Northwell Health | Phase 3 |
| Recruiting | Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma NCT05281731 | Washington University School of Medicine | N/A |
| Recruiting | Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblas NCT06090903 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Gliob NCT05187624 | Hoffmann-La Roche | Phase 1 |
| Completed | Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom NCT05140902 | University of Alabama at Birmingham | N/A |
| Active Not Recruiting | Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and R NCT05095376 | NRG Oncology | Phase 3 |
| Completed | ASP8374 + Cemiplimab in Recurrent Glioma NCT04826393 | Dana-Farber Cancer Institute | Phase 1 |
| Withdrawn | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type NCT05218408 | Celularity Incorporated | Phase 1 / Phase 2 |
| Active Not Recruiting | AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Gliobl NCT04881032 | Centre Jean Perrin | Phase 1 / Phase 2 |
| Suspended | Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma NCT05183204 | Weill Medical College of Cornell University | Phase 2 |
| Recruiting | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer NCT05106296 | Theodore S. Johnson | Phase 1 |
| Active Not Recruiting | Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma NCT05241392 | Beijing Tiantan Hospital | Phase 1 |
| Terminated | RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastom NCT04963413 | University of Florida | Phase 1 |
| Recruiting | The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections NCT04708171 | Erasmus Medical Center | — |
| Recruiting | The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 220 NCT06118723 | Jasper Gerritsen | — |
| Unknown | TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study NCT04717739 | NovoCure Ltd. | — |
| Active Not Recruiting | Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma NCT04019262 | John Flickinger | Phase 1 / Phase 2 |
| Completed | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune NCT04817254 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Abemaciclib + Pembrolizumab In Glioblastoma NCT04118036 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma NCT04910022 | Nerviano Medical Sciences | Phase 1 / Phase 2 |
| Unknown | Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET) NCT05099068 | Centre Leon Berard | N/A |
| Terminated | Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab NCT04681677 | Xoft, Inc. | Phase 2 |
| Active Not Recruiting | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma NCT05076513 | Nader Sanai | EARLY_Phase 1 |
| Completed | Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma NCT04552886 | The Cooper Health System | Phase 1 |
| Completed | The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation NCT04937413 | Duke University | EARLY_Phase 1 |
| Completed | Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma NCT04391062 | University Hospital, Lille | Phase 2 |
| Terminated | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer NCT04982926 | Taiho Oncology, Inc. | Phase 1 |
| Active Not Recruiting | PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Gl NCT03897491 | photonamic GmbH & Co. KG | Phase 2 |
| Completed | SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue NCT04734444 | SonoClear AS | N/A |
| Completed | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients NCT04998864 | InSightec | — |
| Recruiting | ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS NCT04732065 | Sabine Mueller, MD, PhD | Phase 1 |
| Recruiting | Drug Response Testing and Repurposing Using Glioblastoma Organoid NCT06782984 | Chungnam National University Hospital | — |
| Terminated | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma NCT04397679 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Active Not Recruiting | Newly Diagnosed Glioblastoma NCT04959500 | Sun Yat-sen University | Phase 2 |
| Unknown | FKBP51s: a New Molecular Biomarker for Glioblastoma? Pre- and Post-operative Blood Levels Evaluation of FKBP51 NCT05793021 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | Ex VIvo DEtermiNed Cancer Therapy NCT05231655 | Sheffield Teaching Hospitals NHS Foundation Trust | — |
| Unknown | Iodine-125 Brachytherapy Together With Chemotherapy in Patients With Newly Diagnosed Glioblastoma NCT04856852 | The Affiliated Hospital of Qingdao University | N/A |
| Unknown | Effect of Radiotherapy Concurrent of TTFields in Patients With Glioblastoma NCT04902586 | Zhongnan Hospital | N/A |
| Active Not Recruiting | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Mal NCT04913337 | NGM Biopharmaceuticals, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma NCT04747145 | Medical College of Wisconsin | Phase 2 |
| Unknown | MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) NCT04874506 | Matrix Biomed, Inc. | Phase 2 |
| Completed | Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma NCT04730869 | Waikato Hospital | N/A |
| Completed | Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma NCT04474353 | Stanford University | Phase 1 |
| Active Not Recruiting | Surgically Induced Neurological Deficits in Glioblastomas (SIND Study) NCT04007185 | Cambridge University Hospitals NHS Foundation Trust | — |
| Unknown | Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models NCT04970615 | Sümeyye Sezer | — |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Completed | Glioblastoma Response Prediction to Apatinib NCT04814329 | Beijing Sanbo Brain Hospital | — |
| Active Not Recruiting | AB154 Combined With AB122 for Recurrent Glioblastoma NCT04656535 | Yale University | EARLY_Phase 1 |
| Recruiting | Glioblastoma Radiotherapy Using IMRT or Proton Beams NCT04752280 | University Hospital Heidelberg | N/A |
| Active Not Recruiting | Patient-derived Glioma Stem Cell Organoids NCT04868396 | Maastricht Radiation Oncology | — |
| Recruiting | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma NCT04523688 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Terminated | Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT NCT04763031 | Parkridge Medical Center | N/A |
| Active Not Recruiting | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, NCT04661384 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648 | RasCal Therapeutics, Inc. | Phase 1 |
| Terminated | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection NCT04608812 | OncoSynergy, Inc. | Phase 1 |
| Completed | BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and NCT05375318 | Juan M Garcia-Gomez | — |
| Unknown | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors NCT05131763 | Fudan University | Phase 1 |
| Recruiting | LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138) NCT04699773 | University of Maryland, Baltimore | N/A |
| Recruiting | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progre NCT04573192 | Philogen S.p.A. | Phase 1 / Phase 2 |
| Completed | Modulation of Ciliogenesis in Glioma Stem Cells NCT05772767 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Completed | Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Soli NCT04822688 | Thomas Jefferson University | — |
| Active Not Recruiting | Surgical Nivolumab And Ipilimumab For Recurrent GBM NCT04606316 | Patrick Wen, MD | Phase 1 |
| Terminated | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma NCT03868943 | Wake Forest University Health Sciences | Phase 2 |
| Completed | MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma NCT04596930 | Radboud University Medical Center | N/A |
| Completed | Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma NCT04716699 | University of California, Davis | Phase 1 |
| Recruiting | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastom NCT04443010 | Philogen S.p.A. | Phase 1 / Phase 2 |
| Recruiting | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma NCT04590664 | Emory University | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Pamiparib in Newly Diagnosed and rGBM NCT04614909 | Nader Sanai | EARLY_Phase 1 |
| Completed | Biomolecular Analysis for Predicting Response to Regorafenib NCT05759195 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Completed | Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion NCT04566185 | Centre Hospitalier Universitaire de Nīmes | N/A |
| Completed | A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnos NCT03776071 | Denovo Biopharma LLC | Phase 3 |
| Terminated | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NCT04541225 | Nuvation Bio Inc. | Phase 1 |
| Completed | Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients NCT04604158 | Gillian Gresham | N/A |